Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-3318-9708
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date6/10/2019 (Estimated)
OptionableOptionable
Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions
What is Axovant Sciences' stock symbol?
Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."
How were Axovant Sciences' earnings last quarter?
Axovant Sciences Ltd (NASDAQ:AXON) released its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.27). View Axovant Sciences' Earnings History.
When is Axovant Sciences' next earnings date?
What price target have analysts set for AXON?
6 brokers have issued 1 year price targets for Axovant Sciences' shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Axovant Sciences' share price to reach $5.00 in the next year. This suggests a possible upside of 380.8% from the stock's current price. View Analyst Price Targets for Axovant Sciences.
What is the consensus analysts' recommendation for Axovant Sciences?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Sciences.
What are Wall Street analysts saying about Axovant Sciences stock?
Here are some recent quotes from research analysts about Axovant Sciences stock:
- 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (2/12/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to the achievement of target price. Our price target of $7/share is based on an equally-weighted composite of: (a) $6.27/share, as a 35x multiple of taxed and diluted $2.30 discounted back to FY18 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $7.26/share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2018)
Has Axovant Sciences been receiving favorable news coverage?
Media headlines about AXON stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axovant Sciences earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Axovant Sciences' key competitors?
Some companies that are related to Axovant Sciences include Zymeworks (ZYME), Urogen Pharma (URGN), Emisphere Technologies (EMIS), Axsome Therapeutics (AXSM), Collegium Pharmaceutical (COLL), Cyclerion Therapeutics (CYCN), ProQR Therapeutics (PRQR), Corium International (CORI), CytomX Therapeutics (CTMX), BioSpecifics Technologies (BSTC), Corbus Pharmaceuticals (CRBP), Cytokinetics (CYTK), MediciNova (MNOV), Kalvista Pharmaceuticals (KALV) and Five Prime Therapeutics (FPRX).
What other stocks do shareholders of Axovant Sciences own?
Who are Axovant Sciences' key executives?
Axovant Sciences' management team includes the folowing people:
- Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
- Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
- Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 58)
- Dr. David T. Hung, Scientific Advisor of Group (Age 61)
- Dr. Fraser Wright, Chief Technology Officer
When did Axovant Sciences IPO?
(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Who are Axovant Sciences' major shareholders?
Axovant Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.04%). Company insiders that own Axovant Sciences stock include George Bickerstaff, Global Investors Lp Viking and Svf Investments (Uk) Ltd. View Institutional Ownership Trends for Axovant Sciences.
Which institutional investors are buying Axovant Sciences stock?
AXON stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Axovant Sciences stock in the last two years include George Bickerstaff, Global Investors Lp Viking and Svf Investments (Uk) Ltd. View Insider Buying and Selling for Axovant Sciences.
How do I buy shares of Axovant Sciences?
Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axovant Sciences' stock price today?
One share of AXON stock can currently be purchased for approximately $1.04.
How big of a company is Axovant Sciences?
Axovant Sciences has a market capitalization of $127.17 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.
What is Axovant Sciences' official website?
How can I contact Axovant Sciences?
Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.
MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
